argenx

ARGX

Market cap $52.3B

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CSL Limited Sponsored ADR (CSLLY) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

BOSTON--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and services, today announced that argenx SE, a global immunology company, is expanding adoption of the elluminate Clinical Data Cloud® to improve and enhance clinical data processes. The elluminate platform is designed to improve access to and analysis of clinical trial data across sources with a central source of communication for clinical data, including Data Central for collaborative data review.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either CSL Limited Sponsored ADR (CSLLY) or argenex SE (ARGX). But which of these two stocks is more attractive to value investors?

Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART's efficacy and safety across subtypes New biomarker analysis, real-world evidence and post-hoc insights highlight VYVGART's expanding treatment approach in CIDP March 6, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) and pipeline candidates empasiprubart and adimanebart at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago from April 18-22, 2026. “The data we will present at AAN, including new Phase 3 results in ocular myasthenia gravis, demonstrate our relentless efforts to deliver a targeted treatment option to as many patients living with MG as possible,” said Luc Truyen, M.D.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Kamada (KMDA) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?

Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the company in a $9.2 billion all-cash deal announced in November 2025, representing a premium of more than 100% over the prior closing price. Doximity's stock detracted from performance as the company issued disappointing guidance for the next two quarters.

Argenx SE (NASDAQ: ARGX) on Thursday reported upbeat fourth-quarter results and announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).

For 2025, we underperformed the Benchmark, while to a lesser extent also trailing our all-cap international growth Proxy Benchmark. The underperformance was in our view attributable to an abrupt but material correction in several holdings over the potential exposure of quality growth franchises to AI disruption. Lundin Mining Corporation shares rose meaningfully during the fourth quarter after the company raised its 2025 copper production outlook and lowered its cash cost guidance.

argenx SE (ARGX) Q4 2025 Earnings Call Transcript

Argenx SE (NASDAQ: ARGX) on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).